Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer

Signal Transduction and Targeted Therapy

Volumn 1, Issue , 2016, Pages

  Gupta, Harshita B ^a   Clark, Curtis A ^b   Yuan, Bin ^b   Sareddy, Gangadhara ^a   Pandeswara, Srilakshmi ^a   Padron, Alvaro S ^a   Hurez, Vincent ^a   Conejo Garcia, José ^c   Vadlamudi, Ratna ^a,b,d   Li, Rong ^b,d   Curiel, Tyler J ^a,b,d  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c WISTAR INSTITUTE   (United States)

^d University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85026827596     PISSN: 20959907     EISSN: 20593635     Source Type: Journal    
DOI: 10.1038/sigtrans.2016.30     Document Type: Article

References (33)

1. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002; 8: 793–800.
2. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455–2465.
3. Clark CA, Gupta H, Sareddy GR, Pandeswara S, Lao S, Yuan B et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis and autophagy in ovarian cancer and melanoma. Cancer Res 2016; 76: 6964–6974.
4. Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 2015; 162: 1229–1241.
5. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010; 466: 133–137.
6. Li Y, Rogoff HA, Keates S, Gao Y, Murikipudi S, Mikule K et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci USA 2015; 112: 1839–1844.
7. Yao Y, Tao R, Wang X, Wang Y, Mao Y, Zhou LF. B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol 2009; 11: 757–766.
8. Zhi Y, Mou Z, Chen J, He Y, Dong H, Fu X et al. B7H1 expression and epithelial-to-mesenchymal transition phenotypes on colorectal cancer stem-like cells. PLoS One 2015; 10: e0135528.
9. Lee Y, Shin JH, Longmire M, Wang H, Kohrt HE, Chang HY et al. CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1. Clin Cancer Res 2016; 22: 3571–3581.
10. Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E et al. Melanoma cell-intrinsic pd-1 receptor functions promote tumor growth. Cell 2015; 162: 1242–1256.
11. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik Oet al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000; 21: 585–591.
12. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9: 562–567.
13. Dou J, Pan M, Wen P, Li Y, Tang Q, Chu L et al. Isolation and identification of cancer stem-like cells from murine melanoma cell lines. Cell Mol Immunol 2007; 4: 467–472.
14. Gil M, Komorowski MP, Seshadri M, Rokita H, McGray AJ, Opyrchal M et al. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. J Immunol 2014; 193: 5327–5337.
15. Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S et al. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer 2012; 130: 29–39.
16. Liang D, Ma Y, Liu J, Trope CG, Holm R, Nesland JM et al. The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer 2012; 12: 201.
17. Lin PY, Sun L, Thibodeaux SR, Ludwig SM, Vadlamudi RK, Hurez VJ et al. B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol 2010; 185: 2747–2753.
18. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475: 226–230.
19. Schatton T, Schutte U, Frank NY, Zhan Q, Hoerning A, Robles SC et al. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res 2010; 70: 697–708.
20. Civenni G, Walter A, Kobert N, Mihic-Probst D, Zipser M, Belloni B et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res 2011; 71: 3098–3109.
21. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5: 200ra116.
22. Radzisheuskaya A, Silva JC. Do all roads lead to Oct4? the emerging concepts of induced pluripotency. Trends Cell Biol 2014; 24: 275–284.
23. Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene 2010; 29: 2153–2159.
24. Hurez V, Dao V, Liu A, Pandeswara S, Gelfond J, Sun L et al. Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice. Aging Cell 2015; 14: 945–956.
25. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24: 207–212.
26. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–264.
27. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016; 16: 275–287.
28. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4: 127ra37.
29. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP et al. A landscape of driver mutations in melanoma. Cell 2012; 150: 251–263.
30. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609–615.
31. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012; 485: 55–61.
32. Jiang B, Liu F, Liu Z, Zhang T, Hua D. B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway. Tumour Biol 2016; 37: 9465–9472.
33. Ghosh J, Kobayashi M, Ramdas B, Chatterjee A, Ma P, Mali RS et al. S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance. J Clin Invest 2016; 126: 2621–2625.